---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003429"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2026-05-14T20:40:19+00:00"
generated_at: "2026-05-14T20:41:19.838089+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech Q2 net loss widens to $4.2M; progresses EB06 vitiligo Phase 2 prep

## Summary
- Net loss of $4.2M ($0.49/sh) for Q2 FY2026 vs $1.6M ($0.30/sh) in prior year.
- Operating expenses rose $2.7M to $4.3M on $2.3M R&D increase for EB06 and paridiprubart prep.
- Cash and cash equivalents $10.0M; working capital $8.2M as of March 31, 2026.
- EB06 Phase 2 vitiligo study on track; site activations and recruitment expected mid-2026 subject to approval.
- Paridiprubart Phase 3 ARDS data showed consistent treatment benefits across disease subgroups and comorbidities.

## SEC filing metadata
- accession: 0001171843-26-003429
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2026-05-14T20:40:19+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/0001171843-26-003429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/f8k_051326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003429
- JSON: https://secwatch.observer/filing/0001171843-26-003429.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003429.txt

## Key facts
- Earnings Releases
  Edesa Biotech, Inc. reported the three months ended March 31, 2026 results: net income a net loss of $4.2 million, or $0.49 per common share, EPS $0.49 per common share.
  - Period: the three months ended March 31, 2026
  - Net income: a net loss of $4.2 million, or $0.49 per common share
  - EPS: $0.49 per common share
  - Result: reported results
  source text: For the quarter ended March 31, 2026, Edesa reported a net loss of $4.2 million, or $0.49 per common share, compared to a net loss of $1.6 million, or $0.30 per common share, for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/0001171843-26-003429-index.htm
- Earnings Releases
  Edesa Biotech, Inc. reported the six months ended March 31, 2026 results: net income a net loss of $6.5 million, or $0.78 per common share, EPS $0.78 per common share.
  - Period: the six months ended March 31, 2026
  - Net income: a net loss of $6.5 million, or $0.78 per common share
  - EPS: $0.78 per common share
  - Result: reported results
  source text: For the six months ended March 31, 2026, Edesa reported a net loss of $6.5 million, or $0.78 per common share, compared to a net loss of $3.2 million, or $0.74 per common share, for the six months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/0001171843-26-003429-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.